News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Direct Flow Medical, Inc. Transcatheter Aortic Valve System Continues to Demonstrate Excellent Outcomes at Six Months in DISCOVER CE Mark Trial



10/29/2013 10:23:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN FRANCISCO--(BUSINESS WIRE)--Direct Flow MedicalĀ®, Inc., a transcatheter heart valve innovator focused on improving patient outcomes, today announced six-month data from the fully-enrolled DISCOVER CE Mark Trial that continue to affirm the excellent outcomes and strong safety profile of the Direct Flow MedicalĀ® Transcatheter Aortic Valve System. The data, which were presented on Monday at the Transcatheter Cardiovascular Therapeutics (TCT) conference, demonstrated sustained results at six months, with 96 percent freedom from all-cause mortality and no incidence of moderate or severe post-procedural aortic regurgitation. Principal Investigator Joachim Schofer, M.D., from the Medical Care Center, Hamburg, Germany, presented the results.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES